Efficacy and Safety of QL0911 in Adult Patients With Chronic Primary Immune Thrombocytopenia
Clinical trial NCT05621330 · COMPLETED
Trial details
- NCT number
- NCT05621330
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2019-10-18
- Primary completion
- 2021-12-13
- Enrollment
- 216
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.